Scientific Advisors

Robert is Professor and Head of the Old Age Psychiatry department at the Ludwig-Maximilians-University of Munich, and he leads several large dementia studies and initiatives in Germany and the UK.

Robert conducts dementia prevention research at the University of Munich, the German Center for Neurodegenerative Disorders and Imperial College London. His studies apply a range of methodologies to advance the understanding of biological and clinical processes that lead to cognitive decline and associated disability. This includes imaging, fluid biomarker, genomics and cognitive assessments in clinical and epidemiological contexts. The concept of cognitive reserve has always been in the centre of Robert’s scientific activities, because of the great relevance for reducing dementia risk in the population and strengthening vulnerable individuals’ resilience against neurodegeneration. 

Stuart is an experienced Chief Scientific Officer with a three-decade history of working in the clinical research industry, in international pharma, the National Health Service and the private sector. 

He is skilled in pain and cognition studies as well as Good Clinical Practice (GCP), drug development, drug discovery, and medical affairs. He co-founded the now award-winning St Pancras Clinical Research in London with a vision to expand research sites in the UK and beyond. 

Stuart has been Principal Investigator on almost 100 studies, and is UK National Coordinating Investigator on four ongoing cognition studies. He was the Chief Scientific Officer, Director of Pain Research and Member of the Board at the MAC Clinical Research organisation for eight years until 2016, and Educational Supervisor for the UK’s Faculty of Pharmaceutical Medicine until 2015. 

Prior to that he served as Director of Pain Research for Barts and the London NHS Trust from 2000 until the end of 2007, and as International Medical Director of Grünenthal GmbH in Aachen, Germany, from 1988 to 2000.

Mathieu is  a cardiovascular specialist with more than 10 years of experience in academic cardiology. 

Moreover, Mathieu is a Healthcare Executive with over 25 years of experience in management, leadership positions in Clinical Development and Medical Affairs in the world’s largest pharmaceutical companies (Pfizer and Novartis) across multiple therapeutic areas: Hypertension, Heart Failure, Atherosclerosis, AFib, CVRR, Diabetes/Metabolism and CKD. 

Malobal Fellow in Medicines Development (GFMD) for International Federation of Associations  of Pharmaceutical  Physicians and Pharmaceutical Medicine (IFAPP).  

Mathieu has lived and worked in Paris, London and New York. 

Currently, he is residing in Switzerland and is the President of M-GHADANFAR CONSULTING, LIFE SCIENCES in Basel.

Lutz is Professor of Geriatric Psychiatry at the University of Heidelberg, Germany, and Head of the Department of Geriatric Psychiatry at the Central Institute for Mental Health, Mannheim, Germany. 

His major research interest is on translational Alzheimer’s research, biomarkers and the development and evaluation of innovative therapies in Alzheimer’s disease. I have published more than >300 original and review publications in peer-reviewed journals, more than 50 text book chapters on Old Age Psychiatry, 7 book or monographs on dementia-related topics.

Frank is Head of the Department for Neurology and Psychiatry, University Hospital of Cologne

The Jessen group is engaged in clinical research in Alzheimer’s disease (AD) with focus on early disease detection, prevention and treatment. 

The focus of Frank Jessen's working group is the early diagnosis of Alzheimer's disease. Methodologically, the group focuses on clinical and neuropsychological procedures as well as MR imaging. Frank Jessen leads international initiatives to conceptualise the earliest symptoms of Alzheimer's disease, such as subjective cognitive deterioration.

Frank Jessen is also involved in clinical studies of Alzheimer's disease and is the main author of the S3 guideline Dementia in Germany.

He is a member of various committees, including the governing body of the European Alzheimer's Disease Consortium (EADC), the National Institute on Aging Alzheimer's Association (NIA-AA) working group for the development of Alzheimer's research criteria and the ISTAART Advisory Council

Reto W. Kressig is Professor and Chair of Geriatrics at the University of Basel, Switzerland. He is Chief Medical Officer and Directorial Board Member of the University Department of Geriatric Medicine FELIX PLATTER, Basel, Switzerland.  

His scientific work and interests include older adults’ gait biomechanics, physical activity, functional autonomy, nutrition and cognition in relation to principles of geriatric rehabilitation and health prevention among older adults. He was mainly involved as Principal Investigator in numerous Alzheimer drug trials. Further, he has followed up on the development of innovative non-drug approaches for the clinical management of delirium and dementia-related behavioral disorders. 

Prof. Kressig is author of over 150 peer-reviewed original articles, numerous book chapters and other miscellaneous publications. He is Editorial-Member of several international geriatric journals such as the Journal of the American Geriatrics Society (JAGS), Associate Professor of Gerontology at the University of Luxemburg and former Board Member and Secretary of the European Academy for Medicine of Aging.   

Andreas U. Monsch studied clinical psychology, psychopathology, and neurophysiology at the University of Zurich and received his doctorate in 1991. 

From 1991-1994, he worked at the University of California, San Diego (USA), one of the best Alzheimer' disease research centers in the world at the time. From 1994-2002, he was head of research at the Memory Clinic of the Geriatric University Hospital in Basel. In 2001 he received his habilitation and was promoted to Professor of Psychology at the University of Basel in 2003. 

Since 2002, he has been in charge of one of the largest memory clinics in Switzerland, which has relocated to the Felix Platter Hospital in 2016, Basel, and which is now called University Department of Geriatric Medicine FELIX PLATTER. Prof. Monsch's research and teaching focus on "Early diagnosis of dementia" and "Rare causes of dementia". 

He is the current president of the Swiss Association of Neuropsychologists and has served as the chair of the ISTAART Professional Interest Area on Cognition from 2018-2020. He has published over 170 papers and book chapters.